Cargando…

A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine

The major obstacles for tumor vaccine to be surmounted are the lack of versatile property and immunity-inducing effectiveness. Induced pluripotent stem cells (iPSCs) expressed various antigens the same as multiple types of tumors, providing a promising source of wide-spectrum cancer vaccines. The da...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Yuewen, He, Xiaorong, Li, Ying, Han, Ran, Ma, Yuying, Gao, Peng, Qian, Zhiyu, Gu, Yueqing, Li, Siwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386930/
https://www.ncbi.nlm.nih.gov/pubmed/34433569
http://dx.doi.org/10.1126/sciadv.abi6326
_version_ 1783742349302562816
author Zhai, Yuewen
He, Xiaorong
Li, Ying
Han, Ran
Ma, Yuying
Gao, Peng
Qian, Zhiyu
Gu, Yueqing
Li, Siwen
author_facet Zhai, Yuewen
He, Xiaorong
Li, Ying
Han, Ran
Ma, Yuying
Gao, Peng
Qian, Zhiyu
Gu, Yueqing
Li, Siwen
author_sort Zhai, Yuewen
collection PubMed
description The major obstacles for tumor vaccine to be surmounted are the lack of versatile property and immunity-inducing effectiveness. Induced pluripotent stem cells (iPSCs) expressed various antigens the same as multiple types of tumors, providing a promising source of wide-spectrum cancer vaccines. The damaged erythrocyte membrane entrapped by spleen could be developed as antigen deliverer for enhancing acquired immunity. Here, the modified lipid materials were used to dilate erythrocyte membrane to fabricate coalescent nanovector, which not only preserved the biological characteristics of erythrocyte membrane but also remedied the defect of insufficient drug loading capacity. After wrapping iPSC protein, the nanovaccine iPSC@RBC-Mlipo exhibited obvious splenic accumulation, systemic specific antitumor immunity evocation, and effective tumor expansion and metastasis inhibition in mice. Hence, our research may provide a prospective strategy of efficient tumor vaccine for clinical practice.
format Online
Article
Text
id pubmed-8386930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-83869302021-08-31 A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine Zhai, Yuewen He, Xiaorong Li, Ying Han, Ran Ma, Yuying Gao, Peng Qian, Zhiyu Gu, Yueqing Li, Siwen Sci Adv Research Articles The major obstacles for tumor vaccine to be surmounted are the lack of versatile property and immunity-inducing effectiveness. Induced pluripotent stem cells (iPSCs) expressed various antigens the same as multiple types of tumors, providing a promising source of wide-spectrum cancer vaccines. The damaged erythrocyte membrane entrapped by spleen could be developed as antigen deliverer for enhancing acquired immunity. Here, the modified lipid materials were used to dilate erythrocyte membrane to fabricate coalescent nanovector, which not only preserved the biological characteristics of erythrocyte membrane but also remedied the defect of insufficient drug loading capacity. After wrapping iPSC protein, the nanovaccine iPSC@RBC-Mlipo exhibited obvious splenic accumulation, systemic specific antitumor immunity evocation, and effective tumor expansion and metastasis inhibition in mice. Hence, our research may provide a prospective strategy of efficient tumor vaccine for clinical practice. American Association for the Advancement of Science 2021-08-25 /pmc/articles/PMC8386930/ /pubmed/34433569 http://dx.doi.org/10.1126/sciadv.abi6326 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Research Articles
Zhai, Yuewen
He, Xiaorong
Li, Ying
Han, Ran
Ma, Yuying
Gao, Peng
Qian, Zhiyu
Gu, Yueqing
Li, Siwen
A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
title A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
title_full A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
title_fullStr A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
title_full_unstemmed A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
title_short A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
title_sort splenic-targeted versatile antigen courier: ipsc wrapped in coalescent erythrocyte-liposome as tumor nanovaccine
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386930/
https://www.ncbi.nlm.nih.gov/pubmed/34433569
http://dx.doi.org/10.1126/sciadv.abi6326
work_keys_str_mv AT zhaiyuewen asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT hexiaorong asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT liying asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT hanran asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT mayuying asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT gaopeng asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT qianzhiyu asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT guyueqing asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT lisiwen asplenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT zhaiyuewen splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT hexiaorong splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT liying splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT hanran splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT mayuying splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT gaopeng splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT qianzhiyu splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT guyueqing splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine
AT lisiwen splenictargetedversatileantigencourieripscwrappedincoalescenterythrocyteliposomeastumornanovaccine